Udaya Kompella
Concepts (728)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Delivery Systems | 42 | 2026 | 377 | 8.670 |
Why?
| | Retina | 29 | 2026 | 330 | 4.890 |
Why?
| | Nanoparticles | 33 | 2022 | 523 | 4.180 |
Why?
| | Choroid | 15 | 2026 | 81 | 3.410 |
Why?
| | Eye | 13 | 2026 | 112 | 3.100 |
Why?
| | Eye Diseases | 11 | 2021 | 100 | 2.910 |
Why?
| | Sulfonamides | 17 | 2017 | 594 | 2.880 |
Why?
| | Ophthalmic Solutions | 13 | 2025 | 82 | 2.220 |
Why?
| | Pyrazoles | 14 | 2014 | 517 | 2.180 |
Why?
| | Vitreous Body | 15 | 2026 | 118 | 2.120 |
Why?
| | Vascular Endothelial Growth Factor A | 24 | 2017 | 545 | 2.040 |
Why?
| | Triptorelin Pamoate | 14 | 2009 | 19 | 2.040 |
Why?
| | Drug Carriers | 14 | 2019 | 138 | 2.020 |
Why?
| | Cornea | 12 | 2026 | 156 | 1.960 |
Why?
| | Polyglycolic Acid | 16 | 2015 | 44 | 1.910 |
Why?
| | Budesonide | 9 | 2020 | 49 | 1.900 |
Why?
| | Rose Bengal | 2 | 2026 | 2 | 1.880 |
Why?
| | Lactic Acid | 17 | 2015 | 295 | 1.850 |
Why?
| | Delayed-Action Preparations | 18 | 2025 | 192 | 1.840 |
Why?
| | Rabbits | 31 | 2026 | 651 | 1.800 |
Why?
| | Pharmaceutical Preparations | 8 | 2022 | 172 | 1.670 |
Why?
| | Animals | 122 | 2026 | 38107 | 1.640 |
Why?
| | Pigment Epithelium of Eye | 11 | 2012 | 36 | 1.610 |
Why?
| | Sclera | 10 | 2025 | 39 | 1.600 |
Why?
| | Gene Transfer Techniques | 8 | 2014 | 185 | 1.560 |
Why?
| | Diabetes Mellitus, Experimental | 9 | 2018 | 198 | 1.490 |
Why?
| | Particle Size | 16 | 2020 | 386 | 1.440 |
Why?
| | Diabetic Retinopathy | 8 | 2018 | 211 | 1.440 |
Why?
| | Cattle | 20 | 2026 | 940 | 1.420 |
Why?
| | Tandem Mass Spectrometry | 9 | 2026 | 576 | 1.380 |
Why?
| | Dexamethasone | 5 | 2025 | 368 | 1.370 |
Why?
| | Conjunctiva | 14 | 2009 | 52 | 1.310 |
Why?
| | Enzyme Inhibitors | 10 | 2011 | 823 | 1.260 |
Why?
| | Retinal Pigment Epithelium | 7 | 2013 | 81 | 1.250 |
Why?
| | Nanostructures | 4 | 2019 | 105 | 1.240 |
Why?
| | Blood-Retinal Barrier | 6 | 2013 | 13 | 1.240 |
Why?
| | Sulfones | 6 | 2012 | 127 | 1.180 |
Why?
| | Rats | 34 | 2020 | 5586 | 1.170 |
Why?
| | Cyclooxygenase Inhibitors | 6 | 2008 | 82 | 1.160 |
Why?
| | Photosensitizing Agents | 2 | 2025 | 42 | 1.120 |
Why?
| | Melanins | 4 | 2012 | 15 | 1.110 |
Why?
| | Capillary Permeability | 6 | 2011 | 133 | 1.090 |
Why?
| | Drug Compounding | 6 | 2020 | 106 | 1.090 |
Why?
| | Contact Lenses | 2 | 2025 | 13 | 1.090 |
Why?
| | Rats, Sprague-Dawley | 26 | 2020 | 2537 | 1.090 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 7 | 2026 | 344 | 1.060 |
Why?
| | Glucocorticoids | 7 | 2021 | 536 | 1.040 |
Why?
| | Anti-Inflammatory Agents | 7 | 2020 | 474 | 1.030 |
Why?
| | Polymers | 8 | 2013 | 488 | 1.010 |
Why?
| | Anti-Infective Agents | 2 | 2025 | 234 | 0.980 |
Why?
| | Receptors, LHRH | 5 | 2009 | 15 | 0.980 |
Why?
| | Aldehyde Reductase | 5 | 2007 | 31 | 0.960 |
Why?
| | Glycine | 6 | 2009 | 184 | 0.950 |
Why?
| | Photochemotherapy | 2 | 2025 | 39 | 0.940 |
Why?
| | Cysteamine | 1 | 2025 | 7 | 0.930 |
Why?
| | Nanotechnology | 5 | 2019 | 114 | 0.920 |
Why?
| | Vancomycin | 1 | 2026 | 96 | 0.910 |
Why?
| | RNA, Small Interfering | 5 | 2017 | 633 | 0.900 |
Why?
| | Administration, Ophthalmic | 9 | 2025 | 16 | 0.900 |
Why?
| | Biocompatible Materials | 3 | 2026 | 432 | 0.890 |
Why?
| | Nasal Mucosa | 6 | 2009 | 112 | 0.890 |
Why?
| | Keratitis | 1 | 2025 | 21 | 0.880 |
Why?
| | Mite Infestations | 1 | 2025 | 8 | 0.870 |
Why?
| | Blepharitis | 1 | 2025 | 8 | 0.870 |
Why?
| | Eye Infections, Parasitic | 1 | 2025 | 6 | 0.870 |
Why?
| | Intercellular Signaling Peptides and Proteins | 5 | 2013 | 372 | 0.870 |
Why?
| | Celecoxib | 14 | 2014 | 41 | 0.860 |
Why?
| | Naphthalenes | 1 | 2025 | 54 | 0.860 |
Why?
| | Angiogenesis Inhibitors | 8 | 2017 | 239 | 0.830 |
Why?
| | alpha-Crystallin B Chain | 2 | 2022 | 24 | 0.820 |
Why?
| | Epithelial Cells | 8 | 2016 | 1119 | 0.810 |
Why?
| | Retinal Degeneration | 3 | 2020 | 40 | 0.800 |
Why?
| | Dendrimers | 4 | 2012 | 21 | 0.780 |
Why?
| | Endothelial Growth Factors | 5 | 2003 | 61 | 0.770 |
Why?
| | Chromatography, Liquid | 7 | 2022 | 453 | 0.770 |
Why?
| | Lymphokines | 5 | 2003 | 127 | 0.760 |
Why?
| | Gonadotropin-Releasing Hormone | 5 | 2006 | 215 | 0.750 |
Why?
| | Cyprinidae | 1 | 2022 | 22 | 0.740 |
Why?
| | Cyclooxygenase 2 Inhibitors | 6 | 2014 | 24 | 0.740 |
Why?
| | Choroidal Neovascularization | 6 | 2017 | 57 | 0.730 |
Why?
| | Intraocular Pressure | 4 | 2020 | 344 | 0.730 |
Why?
| | Sotalol | 1 | 2022 | 13 | 0.730 |
Why?
| | Administration, Topical | 11 | 2020 | 154 | 0.720 |
Why?
| | Staphylococcus aureus | 1 | 2026 | 459 | 0.710 |
Why?
| | Tomography, Optical Coherence | 2 | 2021 | 283 | 0.710 |
Why?
| | Staphylococcal Infections | 1 | 2026 | 397 | 0.710 |
Why?
| | Insulins | 1 | 2022 | 39 | 0.700 |
Why?
| | Lymphocyte Function-Associated Antigen-1 | 2 | 2012 | 26 | 0.690 |
Why?
| | Awards and Prizes | 1 | 2022 | 72 | 0.690 |
Why?
| | Ophthalmoscopes | 1 | 2021 | 3 | 0.690 |
Why?
| | Tissue Distribution | 10 | 2019 | 334 | 0.690 |
Why?
| | Viscosity | 2 | 2020 | 91 | 0.680 |
Why?
| | Intravitreal Injections | 11 | 2025 | 73 | 0.670 |
Why?
| | Neuroprotective Agents | 1 | 2022 | 146 | 0.670 |
Why?
| | Glaucoma | 4 | 2020 | 267 | 0.660 |
Why?
| | Water | 3 | 2019 | 451 | 0.630 |
Why?
| | Peptides | 5 | 2022 | 992 | 0.620 |
Why?
| | Peptide Fragments | 4 | 2013 | 693 | 0.620 |
Why?
| | Infusion Pumps, Implantable | 1 | 2020 | 26 | 0.620 |
Why?
| | Lens, Crystalline | 4 | 2011 | 136 | 0.620 |
Why?
| | Molecular Chaperones | 3 | 2022 | 200 | 0.620 |
Why?
| | Bleomycin | 3 | 2018 | 255 | 0.610 |
Why?
| | Injections, Intraocular | 3 | 2017 | 14 | 0.610 |
Why?
| | beta-Cyclodextrins | 3 | 2004 | 32 | 0.590 |
Why?
| | Antihypertensive Agents | 2 | 2014 | 519 | 0.580 |
Why?
| | Fluorescent Dyes | 5 | 2018 | 340 | 0.580 |
Why?
| | Drug Liberation | 4 | 2025 | 36 | 0.580 |
Why?
| | Microscopy, Confocal | 8 | 2020 | 322 | 0.570 |
Why?
| | Albumins | 2 | 2019 | 120 | 0.570 |
Why?
| | Genetic Therapy | 5 | 2014 | 303 | 0.570 |
Why?
| | Ephrin-A2 | 1 | 2018 | 4 | 0.570 |
Why?
| | Cell Line | 17 | 2018 | 2814 | 0.550 |
Why?
| | Macular Degeneration | 5 | 2017 | 196 | 0.550 |
Why?
| | Retinal Diseases | 5 | 2014 | 102 | 0.550 |
Why?
| | Biological Transport | 9 | 2012 | 424 | 0.550 |
Why?
| | Adrenal Cortex Hormones | 4 | 2026 | 486 | 0.540 |
Why?
| | Lung Injury | 2 | 2018 | 263 | 0.540 |
Why?
| | Lipid Bilayers | 1 | 2019 | 105 | 0.540 |
Why?
| | Chromatography, High Pressure Liquid | 12 | 2013 | 588 | 0.540 |
Why?
| | Mitochondria | 3 | 2022 | 997 | 0.540 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2018 | 106 | 0.540 |
Why?
| | Biological Availability | 9 | 2020 | 146 | 0.530 |
Why?
| | Lung | 5 | 2018 | 4122 | 0.530 |
Why?
| | Anti-Bacterial Agents | 3 | 2026 | 1942 | 0.530 |
Why?
| | Thiophenes | 2 | 2025 | 117 | 0.530 |
Why?
| | Fluorescein-5-isothiocyanate | 4 | 2016 | 34 | 0.520 |
Why?
| | Microspheres | 4 | 2012 | 142 | 0.520 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2013 | 992 | 0.520 |
Why?
| | Fluorescein | 4 | 2018 | 23 | 0.520 |
Why?
| | Needles | 1 | 2017 | 61 | 0.510 |
Why?
| | Area Under Curve | 7 | 2020 | 335 | 0.510 |
Why?
| | Permeability | 9 | 2018 | 166 | 0.510 |
Why?
| | Technology, Pharmaceutical | 2 | 2010 | 30 | 0.510 |
Why?
| | Retinitis Pigmentosa | 2 | 2014 | 22 | 0.490 |
Why?
| | Rats, Inbred BN | 8 | 2011 | 56 | 0.480 |
Why?
| | Cataract | 2 | 2011 | 240 | 0.470 |
Why?
| | Cephalosporins | 3 | 2002 | 45 | 0.460 |
Why?
| | Nanocapsules | 2 | 2013 | 14 | 0.460 |
Why?
| | Antineoplastic Agents | 6 | 2022 | 2219 | 0.460 |
Why?
| | Electric Impedance | 4 | 2014 | 108 | 0.450 |
Why?
| | Dinoprostone | 3 | 2009 | 179 | 0.440 |
Why?
| | Humans | 67 | 2025 | 146342 | 0.440 |
Why?
| | Epithelium, Corneal | 6 | 2018 | 41 | 0.440 |
Why?
| | Dogs | 4 | 2025 | 517 | 0.430 |
Why?
| | Exfoliation Syndrome | 1 | 2014 | 10 | 0.430 |
Why?
| | Leukostasis | 2 | 2011 | 2 | 0.430 |
Why?
| | RNA, Messenger | 16 | 2012 | 2791 | 0.420 |
Why?
| | Endothelial Cells | 3 | 2018 | 876 | 0.420 |
Why?
| | Drug Implants | 4 | 2025 | 83 | 0.410 |
Why?
| | Pyridones | 2 | 2013 | 210 | 0.410 |
Why?
| | Chemical Phenomena | 2 | 2011 | 75 | 0.400 |
Why?
| | Swine | 6 | 2026 | 821 | 0.400 |
Why?
| | Disease Models, Animal | 15 | 2018 | 4580 | 0.400 |
Why?
| | Light | 2 | 2013 | 401 | 0.390 |
Why?
| | Chloroquine | 2 | 2012 | 54 | 0.390 |
Why?
| | Posterior Eye Segment | 1 | 2013 | 3 | 0.390 |
Why?
| | Transferrin | 3 | 2009 | 48 | 0.390 |
Why?
| | Eye Proteins | 2 | 2012 | 93 | 0.390 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2018 | 1224 | 0.390 |
Why?
| | Serum Albumin, Bovine | 1 | 2013 | 63 | 0.390 |
Why?
| | Glaucoma, Open-Angle | 1 | 2014 | 109 | 0.380 |
Why?
| | Adrenergic beta-Antagonists | 4 | 2011 | 253 | 0.380 |
Why?
| | Cell Proliferation | 8 | 2017 | 2502 | 0.380 |
Why?
| | Poloxamer | 2 | 2002 | 11 | 0.370 |
Why?
| | Male | 45 | 2025 | 73396 | 0.370 |
Why?
| | Salicylic Acid | 1 | 2012 | 10 | 0.370 |
Why?
| | Capsid Proteins | 1 | 2013 | 94 | 0.370 |
Why?
| | Adenoviridae | 1 | 2013 | 197 | 0.370 |
Why?
| | Nanomedicine | 1 | 2013 | 47 | 0.370 |
Why?
| | Fluocinolone Acetonide | 2 | 2011 | 14 | 0.370 |
Why?
| | Bronchodilator Agents | 2 | 2005 | 186 | 0.370 |
Why?
| | Cyclooxygenase 2 | 4 | 2012 | 166 | 0.370 |
Why?
| | Phenylalanine | 1 | 2012 | 69 | 0.360 |
Why?
| | Pyrimidines | 2 | 2017 | 532 | 0.360 |
Why?
| | Mice | 23 | 2023 | 18297 | 0.360 |
Why?
| | Chlorides | 4 | 1998 | 138 | 0.360 |
Why?
| | Corneal Neovascularization | 4 | 2015 | 15 | 0.350 |
Why?
| | Pulmonary Fibrosis | 2 | 2013 | 395 | 0.350 |
Why?
| | Carbon Dioxide | 4 | 2013 | 228 | 0.350 |
Why?
| | Tyrosine | 1 | 2012 | 217 | 0.350 |
Why?
| | Probenecid | 2 | 2009 | 8 | 0.350 |
Why?
| | Injections | 8 | 2011 | 201 | 0.340 |
Why?
| | Geographic Atrophy | 1 | 2013 | 105 | 0.340 |
Why?
| | Antioxidants | 2 | 2014 | 544 | 0.340 |
Why?
| | STAT1 Transcription Factor | 1 | 2011 | 68 | 0.340 |
Why?
| | Thiazines | 1 | 2011 | 13 | 0.340 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2009 | 109 | 0.330 |
Why?
| | Macular Edema | 1 | 2011 | 49 | 0.330 |
Why?
| | Absorbable Implants | 2 | 2020 | 38 | 0.330 |
Why?
| | Bevacizumab | 4 | 2017 | 169 | 0.330 |
Why?
| | Mitochondrial Diseases | 1 | 2011 | 94 | 0.320 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 9 | 2012 | 974 | 0.320 |
Why?
| | Oligonucleotides, Antisense | 3 | 2009 | 122 | 0.320 |
Why?
| | Polyglactin 910 | 2 | 2012 | 6 | 0.320 |
Why?
| | Poly G | 1 | 2010 | 2 | 0.320 |
Why?
| | Oxidative Stress | 5 | 2021 | 1369 | 0.320 |
Why?
| | Suspensions | 3 | 2020 | 28 | 0.320 |
Why?
| | Diclofenac | 2 | 2009 | 14 | 0.310 |
Why?
| | Trabecular Meshwork | 1 | 2011 | 74 | 0.310 |
Why?
| | Vascular Endothelial Growth Factors | 6 | 2011 | 77 | 0.310 |
Why?
| | Solvents | 5 | 2013 | 112 | 0.310 |
Why?
| | Fluoroquinolones | 1 | 2010 | 44 | 0.310 |
Why?
| | Micelles | 1 | 2010 | 38 | 0.310 |
Why?
| | Solubility | 5 | 2011 | 240 | 0.310 |
Why?
| | Vascular Diseases | 1 | 2012 | 252 | 0.310 |
Why?
| | Retinal Neovascularization | 4 | 2015 | 29 | 0.300 |
Why?
| | Adjuvants, Pharmaceutic | 1 | 2009 | 15 | 0.300 |
Why?
| | Drug Stability | 6 | 2011 | 172 | 0.300 |
Why?
| | Materials Testing | 2 | 2026 | 345 | 0.300 |
Why?
| | Gene Expression | 5 | 2018 | 1463 | 0.300 |
Why?
| | Receptors, Glucocorticoid | 2 | 2009 | 132 | 0.300 |
Why?
| | Chorioallantoic Membrane | 1 | 2009 | 3 | 0.290 |
Why?
| | Porosity | 4 | 2013 | 95 | 0.290 |
Why?
| | Cell Survival | 6 | 2013 | 1105 | 0.290 |
Why?
| | Taxoids | 1 | 2009 | 115 | 0.290 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2008 | 18 | 0.280 |
Why?
| | Receptor, EphA2 | 2 | 2018 | 17 | 0.280 |
Why?
| | Plasmids | 5 | 2017 | 373 | 0.280 |
Why?
| | Models, Animal | 2 | 2020 | 387 | 0.280 |
Why?
| | Endothelium, Corneal | 2 | 2021 | 19 | 0.280 |
Why?
| | Spectroscopy, Fourier Transform Infrared | 4 | 2010 | 83 | 0.280 |
Why?
| | Species Specificity | 2 | 2026 | 543 | 0.280 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2017 | 2022 | 0.270 |
Why?
| | Pharmacokinetics | 4 | 2012 | 33 | 0.270 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2011 | 429 | 0.270 |
Why?
| | Injections, Intravenous | 5 | 2017 | 197 | 0.270 |
Why?
| | Models, Biological | 4 | 2025 | 1761 | 0.270 |
Why?
| | Lung Neoplasms | 5 | 2017 | 2675 | 0.270 |
Why?
| | Eye Color | 1 | 2008 | 3 | 0.270 |
Why?
| | Green Fluorescent Proteins | 1 | 2009 | 408 | 0.270 |
Why?
| | Bruch Membrane | 2 | 2011 | 8 | 0.270 |
Why?
| | Retinal Pigments | 1 | 2007 | 6 | 0.270 |
Why?
| | Drug Administration Routes | 4 | 2009 | 41 | 0.270 |
Why?
| | DNA-Binding Proteins | 3 | 2023 | 1468 | 0.260 |
Why?
| | Lasers | 3 | 2021 | 127 | 0.260 |
Why?
| | Anthraquinones | 1 | 2007 | 10 | 0.260 |
Why?
| | Imidazolidines | 1 | 2007 | 10 | 0.260 |
Why?
| | Chemistry, Pharmaceutical | 4 | 2012 | 116 | 0.250 |
Why?
| | Fluorophotometry | 2 | 2020 | 3 | 0.250 |
Why?
| | Indomethacin | 2 | 2004 | 76 | 0.250 |
Why?
| | Computer Simulation | 3 | 2025 | 1014 | 0.250 |
Why?
| | DNA | 2 | 2013 | 1421 | 0.250 |
Why?
| | ELAV-Like Protein 1 | 2 | 2017 | 17 | 0.250 |
Why?
| | Microscopy, Electron, Scanning | 5 | 2005 | 193 | 0.250 |
Why?
| | Macula Lutea | 1 | 2007 | 21 | 0.250 |
Why?
| | Rhodamines | 1 | 2006 | 20 | 0.240 |
Why?
| | Mannitol | 1 | 2006 | 42 | 0.240 |
Why?
| | Medical Oncology | 1 | 2009 | 345 | 0.240 |
Why?
| | Serum Albumin | 1 | 2007 | 147 | 0.240 |
Why?
| | Blotting, Western | 7 | 2013 | 1177 | 0.240 |
Why?
| | Reproducibility of Results | 3 | 2022 | 3416 | 0.230 |
Why?
| | Time Factors | 13 | 2015 | 7109 | 0.230 |
Why?
| | Hydrogen-Ion Concentration | 5 | 2015 | 534 | 0.220 |
Why?
| | Aldehydes | 2 | 2005 | 140 | 0.220 |
Why?
| | Vitamin E | 1 | 2025 | 123 | 0.220 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 5 | 2013 | 846 | 0.220 |
Why?
| | Mites | 1 | 2025 | 7 | 0.220 |
Why?
| | Superoxide Dismutase | 1 | 2007 | 307 | 0.220 |
Why?
| | Oxazoles | 1 | 2025 | 48 | 0.220 |
Why?
| | Protein Kinase Inhibitors | 1 | 2011 | 983 | 0.220 |
Why?
| | Triamcinolone Acetonide | 3 | 2021 | 20 | 0.210 |
Why?
| | Buserelin | 1 | 2004 | 1 | 0.210 |
Why?
| | Cats | 1 | 2025 | 226 | 0.210 |
Why?
| | Glutathione | 2 | 2005 | 369 | 0.210 |
Why?
| | DNA Helicases | 2 | 2023 | 138 | 0.200 |
Why?
| | Oligopeptides | 3 | 2011 | 264 | 0.200 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 2013 | 627 | 0.200 |
Why?
| | Orphan Nuclear Receptors | 3 | 2014 | 14 | 0.200 |
Why?
| | In Vitro Techniques | 6 | 2012 | 1041 | 0.200 |
Why?
| | Cell Membrane Permeability | 4 | 2018 | 88 | 0.200 |
Why?
| | Cell Line, Tumor | 7 | 2022 | 3545 | 0.200 |
Why?
| | Lysosomes | 2 | 2015 | 134 | 0.200 |
Why?
| | Protein Synthesis Inhibitors | 2 | 2014 | 48 | 0.190 |
Why?
| | Mice, Inbred BALB C | 6 | 2014 | 1244 | 0.190 |
Why?
| | Half-Life | 3 | 2009 | 157 | 0.190 |
Why?
| | Circular Dichroism | 2 | 2013 | 149 | 0.190 |
Why?
| | Respiratory System | 1 | 2004 | 150 | 0.190 |
Why?
| | Cell Cycle | 3 | 2013 | 595 | 0.190 |
Why?
| | Octanols | 1 | 2022 | 1 | 0.180 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2002 | 48 | 0.180 |
Why?
| | Arthritis, Rheumatoid | 1 | 2011 | 1185 | 0.180 |
Why?
| | Polyesters | 3 | 2013 | 76 | 0.180 |
Why?
| | Linear Models | 3 | 2009 | 857 | 0.180 |
Why?
| | Protein Structure, Secondary | 2 | 2013 | 357 | 0.180 |
Why?
| | alpha-Cyclodextrins | 1 | 2001 | 1 | 0.180 |
Why?
| | Thiazolidinediones | 2 | 2013 | 142 | 0.180 |
Why?
| | Protein Aggregates | 1 | 2022 | 87 | 0.170 |
Why?
| | Transfection | 3 | 2015 | 916 | 0.170 |
Why?
| | Cyclodextrins | 1 | 2001 | 11 | 0.170 |
Why?
| | Prostatic Neoplasms | 1 | 2009 | 972 | 0.170 |
Why?
| | Chymotrypsin | 1 | 2001 | 23 | 0.170 |
Why?
| | Temperature | 5 | 2004 | 635 | 0.170 |
Why?
| | Rhodopsin | 2 | 2011 | 11 | 0.170 |
Why?
| | Drug Evaluation, Preclinical | 4 | 2017 | 195 | 0.170 |
Why?
| | Electroretinography | 4 | 2018 | 51 | 0.170 |
Why?
| | Cystinosis | 1 | 2021 | 1 | 0.170 |
Why?
| | Liposomes | 3 | 2011 | 269 | 0.170 |
Why?
| | Cystine | 1 | 2021 | 17 | 0.170 |
Why?
| | Models, Molecular | 2 | 2019 | 1574 | 0.170 |
Why?
| | Zinc Compounds | 2 | 1998 | 8 | 0.170 |
Why?
| | Edetic Acid | 2 | 1998 | 47 | 0.160 |
Why?
| | Oncogenes | 2 | 2022 | 113 | 0.160 |
Why?
| | Carboplatin | 2 | 2013 | 168 | 0.160 |
Why?
| | Molecular Weight | 2 | 2013 | 295 | 0.160 |
Why?
| | Eye Burns | 2 | 2013 | 14 | 0.160 |
Why?
| | Hypromellose Derivatives | 1 | 2020 | 2 | 0.160 |
Why?
| | Proteins | 2 | 2001 | 1022 | 0.160 |
Why?
| | Therapeutic Equivalency | 1 | 2020 | 31 | 0.160 |
Why?
| | Mice, Nude | 3 | 2017 | 668 | 0.160 |
Why?
| | Brain | 2 | 2011 | 2991 | 0.160 |
Why?
| | Cytoskeleton | 1 | 2021 | 180 | 0.160 |
Why?
| | Fluorescein Angiography | 4 | 2017 | 197 | 0.160 |
Why?
| | Uveitis | 2 | 2014 | 152 | 0.160 |
Why?
| | Respiratory Mucosa | 1 | 2003 | 323 | 0.160 |
Why?
| | Collagen | 2 | 2013 | 460 | 0.160 |
Why?
| | Corneal Stroma | 2 | 2018 | 24 | 0.160 |
Why?
| | Symporters | 1 | 2020 | 49 | 0.160 |
Why?
| | Cholic Acids | 2 | 2011 | 13 | 0.150 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 2 | 2013 | 74 | 0.150 |
Why?
| | Prodrugs | 1 | 2000 | 54 | 0.150 |
Why?
| | Benzo(a)pyrene | 2 | 2013 | 8 | 0.150 |
Why?
| | Pyramidal Cells | 1 | 2020 | 80 | 0.150 |
Why?
| | 2-Hydroxypropyl-beta-cyclodextrin | 3 | 2004 | 7 | 0.150 |
Why?
| | Body Weight | 3 | 2011 | 968 | 0.150 |
Why?
| | Administration, Oral | 3 | 2012 | 872 | 0.150 |
Why?
| | Ophthalmology | 1 | 2021 | 122 | 0.150 |
Why?
| | Thermodynamics | 1 | 2001 | 420 | 0.150 |
Why?
| | Prednisolone | 2 | 2011 | 65 | 0.150 |
Why?
| | Aqueous Humor | 3 | 2025 | 41 | 0.150 |
Why?
| | Macaca fascicularis | 2 | 2025 | 70 | 0.150 |
Why?
| | Gene Expression Regulation | 6 | 2018 | 2599 | 0.140 |
Why?
| | Synovial Fluid | 1 | 1999 | 69 | 0.140 |
Why?
| | Adsorption | 1 | 2019 | 154 | 0.140 |
Why?
| | Chitosan | 2 | 2016 | 39 | 0.140 |
Why?
| | Drug Administration Schedule | 2 | 2011 | 790 | 0.140 |
Why?
| | Molecular Targeted Therapy | 2 | 2011 | 447 | 0.140 |
Why?
| | Chemistry, Physical | 2 | 2009 | 36 | 0.130 |
Why?
| | Surface Properties | 1 | 2019 | 384 | 0.130 |
Why?
| | Neovascularization, Pathologic | 2 | 2013 | 287 | 0.130 |
Why?
| | Cells, Cultured | 6 | 2018 | 4118 | 0.130 |
Why?
| | Gene Silencing | 3 | 2017 | 200 | 0.130 |
Why?
| | Drug Interactions | 3 | 2013 | 405 | 0.130 |
Why?
| | Endoplasmic Reticulum | 2 | 2018 | 268 | 0.130 |
Why?
| | Molecular Structure | 2 | 2009 | 484 | 0.130 |
Why?
| | Regional Blood Flow | 2 | 2011 | 507 | 0.130 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2018 | 120 | 0.130 |
Why?
| | Mice, Inbred C57BL | 8 | 2018 | 6034 | 0.130 |
Why?
| | Glycoproteins | 1 | 1999 | 356 | 0.130 |
Why?
| | Glioma | 1 | 2022 | 425 | 0.130 |
Why?
| | Action Potentials | 1 | 2020 | 500 | 0.130 |
Why?
| | Drug Combinations | 2 | 2011 | 400 | 0.130 |
Why?
| | Excipients | 2 | 2001 | 55 | 0.120 |
Why?
| | Turbinates | 2 | 2008 | 14 | 0.120 |
Why?
| | Drug Monitoring | 1 | 2020 | 399 | 0.120 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2013 | 642 | 0.120 |
Why?
| | Mifepristone | 2 | 2009 | 45 | 0.120 |
Why?
| | Dextran Sulfate | 1 | 2016 | 93 | 0.120 |
Why?
| | RNAi Therapeutics | 1 | 2016 | 7 | 0.120 |
Why?
| | Folate Receptor 1 | 1 | 2016 | 17 | 0.120 |
Why?
| | 2,4-Dinitrophenol | 3 | 2004 | 8 | 0.120 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 2 | 2013 | 45 | 0.120 |
Why?
| | Transient Receptor Potential Channels | 1 | 2015 | 5 | 0.110 |
Why?
| | Indazoles | 2 | 2017 | 86 | 0.110 |
Why?
| | Vacuolar Proton-Translocating ATPases | 1 | 2015 | 15 | 0.110 |
Why?
| | Immunoconjugates | 1 | 2017 | 138 | 0.110 |
Why?
| | Presenilin-1 | 1 | 2015 | 34 | 0.110 |
Why?
| | Central Nervous System | 1 | 1998 | 278 | 0.110 |
Why?
| | Signal Transduction | 2 | 2013 | 5246 | 0.110 |
Why?
| | Cyclic AMP | 1 | 1996 | 208 | 0.110 |
Why?
| | Wnt3A Protein | 1 | 2015 | 11 | 0.110 |
Why?
| | Receptors, LDL | 1 | 2015 | 53 | 0.110 |
Why?
| | Precision Medicine | 1 | 2019 | 462 | 0.110 |
Why?
| | Absorption | 2 | 2004 | 60 | 0.110 |
Why?
| | Mucous Membrane | 3 | 1996 | 130 | 0.110 |
Why?
| | Sodium | 2 | 1996 | 196 | 0.110 |
Why?
| | Administration, Intranasal | 2 | 2009 | 95 | 0.110 |
Why?
| | Vaccine Potency | 1 | 2014 | 6 | 0.100 |
Why?
| | Hippocampus | 1 | 2020 | 989 | 0.100 |
Why?
| | Phagocytosis | 2 | 2013 | 298 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2014 | 334 | 0.100 |
Why?
| | Aluminum Hydroxide | 1 | 2014 | 13 | 0.100 |
Why?
| | Injections, Intraperitoneal | 2 | 2004 | 115 | 0.100 |
Why?
| | Nuclear Receptor Subfamily 1, Group D, Member 1 | 1 | 2014 | 3 | 0.100 |
Why?
| | Plasminogen | 2 | 2011 | 26 | 0.100 |
Why?
| | Retinal Vessels | 1 | 2015 | 79 | 0.100 |
Why?
| | Female | 16 | 2020 | 79499 | 0.100 |
Why?
| | Microbial Sensitivity Tests | 2 | 2010 | 367 | 0.100 |
Why?
| | Freezing | 1 | 2014 | 84 | 0.100 |
Why?
| | Eye Diseases, Hereditary | 1 | 2014 | 15 | 0.100 |
Why?
| | Hepatitis B Vaccines | 1 | 2014 | 43 | 0.100 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 2 | 2004 | 76 | 0.100 |
Why?
| | Fibrosis | 2 | 2013 | 568 | 0.100 |
Why?
| | Acetophenones | 1 | 2013 | 13 | 0.100 |
Why?
| | Tight Junctions | 1 | 2014 | 87 | 0.100 |
Why?
| | Withanolides | 1 | 2013 | 2 | 0.100 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2014 | 128 | 0.100 |
Why?
| | Blood Glucose | 3 | 2011 | 2360 | 0.100 |
Why?
| | Calorimetry, Differential Scanning | 2 | 2004 | 35 | 0.100 |
Why?
| | Micro-Electrical-Mechanical Systems | 1 | 2013 | 7 | 0.100 |
Why?
| | Chromatography, Gel | 1 | 2013 | 131 | 0.100 |
Why?
| | Cholesterol | 2 | 2016 | 411 | 0.100 |
Why?
| | Retinal Rod Photoreceptor Cells | 1 | 2013 | 17 | 0.100 |
Why?
| | Cell Shape | 1 | 2013 | 56 | 0.100 |
Why?
| | alpha-Crystallin A Chain | 1 | 2013 | 13 | 0.100 |
Why?
| | Gemfibrozil | 1 | 2013 | 9 | 0.090 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2013 | 113 | 0.090 |
Why?
| | Scattering, Radiation | 1 | 2013 | 98 | 0.090 |
Why?
| | Vimentin | 1 | 2013 | 47 | 0.090 |
Why?
| | Capsid | 1 | 2013 | 94 | 0.090 |
Why?
| | Monophenol Monooxygenase | 1 | 2012 | 7 | 0.090 |
Why?
| | Madin Darby Canine Kidney Cells | 1 | 2012 | 17 | 0.090 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 143 | 0.090 |
Why?
| | Receptors, Transferrin | 2 | 2017 | 28 | 0.090 |
Why?
| | Trachea | 2 | 2005 | 253 | 0.090 |
Why?
| | Corneal Injuries | 1 | 2013 | 42 | 0.090 |
Why?
| | Pressure | 1 | 2013 | 221 | 0.090 |
Why?
| | Wnt Signaling Pathway | 1 | 2015 | 211 | 0.090 |
Why?
| | Timolol | 2 | 2011 | 14 | 0.090 |
Why?
| | Bronchoalveolar Lavage | 1 | 2012 | 90 | 0.090 |
Why?
| | Adjuvants, Immunologic | 1 | 2014 | 245 | 0.090 |
Why?
| | Levodopa | 1 | 2012 | 40 | 0.090 |
Why?
| | Protein Stability | 1 | 2013 | 180 | 0.090 |
Why?
| | Gels | 2 | 2002 | 86 | 0.090 |
Why?
| | Ouabain | 3 | 1998 | 17 | 0.090 |
Why?
| | Cell Count | 1 | 2013 | 315 | 0.090 |
Why?
| | Sensitivity and Specificity | 2 | 2008 | 1998 | 0.090 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 197 | 0.090 |
Why?
| | Apoptosis | 4 | 2013 | 2439 | 0.090 |
Why?
| | Pigmentation | 1 | 2012 | 50 | 0.090 |
Why?
| | Colorimetry | 1 | 2012 | 12 | 0.090 |
Why?
| | Lymphangiogenesis | 1 | 2012 | 28 | 0.090 |
Why?
| | Hypolipidemic Agents | 1 | 2013 | 89 | 0.090 |
Why?
| | Doxycycline | 1 | 2012 | 61 | 0.090 |
Why?
| | Cloning, Molecular | 1 | 2013 | 526 | 0.090 |
Why?
| | Vision Disorders | 1 | 2014 | 179 | 0.090 |
Why?
| | Corneal Diseases | 1 | 2012 | 48 | 0.090 |
Why?
| | Treatment Outcome | 6 | 2014 | 11821 | 0.090 |
Why?
| | Swine, Miniature | 1 | 2012 | 88 | 0.090 |
Why?
| | Membrane Transport Proteins | 1 | 2013 | 154 | 0.090 |
Why?
| | Microscopy, Phase-Contrast | 1 | 2011 | 17 | 0.090 |
Why?
| | MicroRNAs | 1 | 2018 | 699 | 0.090 |
Why?
| | Paclitaxel | 1 | 2013 | 260 | 0.090 |
Why?
| | Drug Discovery | 1 | 2012 | 154 | 0.090 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 952 | 0.090 |
Why?
| | Carbonic Anhydrase Inhibitors | 1 | 2011 | 14 | 0.090 |
Why?
| | Carbon | 1 | 2012 | 176 | 0.090 |
Why?
| | Propranolol | 1 | 2011 | 44 | 0.080 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2011 | 75 | 0.080 |
Why?
| | Inflammation | 2 | 2020 | 2919 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2017 | 930 | 0.080 |
Why?
| | Chemical Warfare Agents | 1 | 2012 | 89 | 0.080 |
Why?
| | Optic Nerve | 1 | 2011 | 65 | 0.080 |
Why?
| | Quinoxalines | 1 | 2011 | 65 | 0.080 |
Why?
| | Silymarin | 1 | 2012 | 147 | 0.080 |
Why?
| | Curcumin | 1 | 2011 | 29 | 0.080 |
Why?
| | Diffusion Chambers, Culture | 2 | 2010 | 9 | 0.080 |
Why?
| | HEK293 Cells | 1 | 2013 | 750 | 0.080 |
Why?
| | Biological Transport, Active | 4 | 2010 | 69 | 0.080 |
Why?
| | Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2011 | 80 | 0.080 |
Why?
| | Amino Acids | 1 | 1995 | 515 | 0.080 |
Why?
| | Rats, Wistar | 1 | 2012 | 451 | 0.080 |
Why?
| | Ion Transport | 3 | 1996 | 61 | 0.080 |
Why?
| | Gold | 2 | 2022 | 118 | 0.080 |
Why?
| | Lipogenesis | 1 | 2011 | 62 | 0.080 |
Why?
| | Wound Healing | 1 | 2013 | 354 | 0.080 |
Why?
| | Pregnadienediols | 1 | 2010 | 3 | 0.080 |
Why?
| | Chromatography, Supercritical Fluid | 1 | 2009 | 3 | 0.080 |
Why?
| | Calorimetry | 1 | 2010 | 69 | 0.080 |
Why?
| | Polymorphism, Genetic | 1 | 2013 | 612 | 0.080 |
Why?
| | Stress, Physiological | 1 | 2013 | 450 | 0.080 |
Why?
| | Interleukin-10 | 1 | 2011 | 310 | 0.080 |
Why?
| | Leukocytes | 1 | 2011 | 301 | 0.080 |
Why?
| | Emulsions | 1 | 2009 | 58 | 0.080 |
Why?
| | Blood Proteins | 1 | 2011 | 239 | 0.070 |
Why?
| | Dosage Forms | 1 | 2009 | 11 | 0.070 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5899 | 0.070 |
Why?
| | Graft Survival | 1 | 2012 | 523 | 0.070 |
Why?
| | Neoplasm Transplantation | 1 | 2009 | 238 | 0.070 |
Why?
| | Calcium | 1 | 2015 | 1181 | 0.070 |
Why?
| | Flow Cytometry | 2 | 2012 | 1163 | 0.070 |
Why?
| | Anticholesteremic Agents | 1 | 2011 | 156 | 0.070 |
Why?
| | Retinal Neoplasms | 1 | 2009 | 47 | 0.070 |
Why?
| | Chick Embryo | 1 | 2009 | 132 | 0.070 |
Why?
| | Retinoblastoma | 1 | 2009 | 53 | 0.070 |
Why?
| | Genetic Vectors | 2 | 2007 | 327 | 0.070 |
Why?
| | Vinblastine | 1 | 2009 | 75 | 0.070 |
Why?
| | Cell Membrane | 1 | 2012 | 701 | 0.070 |
Why?
| | Least-Squares Analysis | 1 | 2008 | 73 | 0.070 |
Why?
| | Drug Synergism | 1 | 2009 | 354 | 0.070 |
Why?
| | Calibration | 1 | 2008 | 154 | 0.070 |
Why?
| | Aging | 1 | 2019 | 1996 | 0.070 |
Why?
| | Validation Studies as Topic | 1 | 2008 | 23 | 0.070 |
Why?
| | Neoplasms | 1 | 2023 | 2954 | 0.070 |
Why?
| | Tumor Burden | 1 | 2009 | 326 | 0.070 |
Why?
| | Thionucleotides | 1 | 2007 | 35 | 0.070 |
Why?
| | Mice, Transgenic | 4 | 2018 | 2134 | 0.070 |
Why?
| | Hydrocortisone | 1 | 2010 | 303 | 0.070 |
Why?
| | Tosylphenylalanyl Chloromethyl Ketone | 2 | 1998 | 3 | 0.070 |
Why?
| | Ethylmaleimide | 2 | 1998 | 18 | 0.070 |
Why?
| | Neovascularization, Physiologic | 1 | 2009 | 189 | 0.060 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2007 | 116 | 0.060 |
Why?
| | Caveolae | 1 | 2007 | 15 | 0.060 |
Why?
| | Clathrin | 1 | 2007 | 26 | 0.060 |
Why?
| | Cell Movement | 3 | 2017 | 951 | 0.060 |
Why?
| | Pharmaceutical Vehicles | 1 | 2007 | 12 | 0.060 |
Why?
| | Models, Anatomic | 1 | 2008 | 87 | 0.060 |
Why?
| | Mydriasis | 1 | 2007 | 10 | 0.060 |
Why?
| | Cells | 1 | 2007 | 24 | 0.060 |
Why?
| | Galactose | 1 | 2007 | 34 | 0.060 |
Why?
| | Vacuoles | 1 | 2007 | 36 | 0.060 |
Why?
| | Glycopeptides | 2 | 1998 | 48 | 0.060 |
Why?
| | Lipid Metabolism | 1 | 2011 | 533 | 0.060 |
Why?
| | Burns, Chemical | 1 | 2007 | 32 | 0.060 |
Why?
| | Pulmonary Alveoli | 1 | 2009 | 385 | 0.060 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2010 | 253 | 0.060 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2008 | 213 | 0.060 |
Why?
| | Aptamers, Nucleotide | 1 | 2007 | 88 | 0.060 |
Why?
| | Diffusion | 2 | 2009 | 119 | 0.060 |
Why?
| | Macaca mulatta | 1 | 2007 | 188 | 0.060 |
Why?
| | Ketorolac Tromethamine | 1 | 2006 | 4 | 0.060 |
Why?
| | Doxorubicin | 1 | 2009 | 416 | 0.060 |
Why?
| | Macrophages | 2 | 2011 | 1532 | 0.060 |
Why?
| | Cell Hypoxia | 1 | 2007 | 249 | 0.060 |
Why?
| | Software | 1 | 2011 | 676 | 0.060 |
Why?
| | Mass Spectrometry | 1 | 2009 | 729 | 0.060 |
Why?
| | Electrophysiology | 3 | 1996 | 219 | 0.060 |
Why?
| | Thiobarbituric Acid Reactive Substances | 1 | 2005 | 29 | 0.060 |
Why?
| | Glutathione Disulfide | 1 | 2005 | 30 | 0.060 |
Why?
| | Hydrogels | 1 | 2012 | 708 | 0.050 |
Why?
| | Alzheimer Disease | 1 | 2011 | 641 | 0.050 |
Why?
| | Dextrans | 2 | 2016 | 83 | 0.050 |
Why?
| | Lymph Nodes | 1 | 2008 | 511 | 0.050 |
Why?
| | Injections, Intramuscular | 1 | 2005 | 140 | 0.050 |
Why?
| | Cyclooxygenase 1 | 1 | 2004 | 27 | 0.050 |
Why?
| | Carcinogens | 1 | 2005 | 112 | 0.050 |
Why?
| | Kidney | 1 | 2012 | 1498 | 0.050 |
Why?
| | Oligoribonucleotides, Antisense | 1 | 2004 | 3 | 0.050 |
Why?
| | Pharmaceutical Solutions | 1 | 2004 | 14 | 0.050 |
Why?
| | Atherosclerosis | 1 | 2008 | 410 | 0.050 |
Why?
| | X-Ray Diffraction | 1 | 2004 | 76 | 0.050 |
Why?
| | Powders | 1 | 2004 | 45 | 0.050 |
Why?
| | Immunohistochemistry | 3 | 2013 | 1712 | 0.050 |
Why?
| | Cell Nucleus | 1 | 2007 | 584 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1512 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 1 | 2004 | 345 | 0.050 |
Why?
| | Cell Culture Techniques | 1 | 2006 | 371 | 0.050 |
Why?
| | Cytochrome P-450 CYP2C8 | 2 | 2013 | 14 | 0.050 |
Why?
| | Hormone Antagonists | 1 | 2003 | 32 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 1998 | 0.050 |
Why?
| | Hypoglycemic Agents | 1 | 2013 | 1412 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2008 | 2113 | 0.050 |
Why?
| | Diabetes Mellitus | 1 | 2011 | 1101 | 0.050 |
Why?
| | Administration, Inhalation | 1 | 2004 | 567 | 0.050 |
Why?
| | Cytosol | 1 | 2003 | 215 | 0.050 |
Why?
| | Theranostic Nanomedicine | 1 | 2022 | 14 | 0.040 |
Why?
| | Flow Injection Analysis | 1 | 2002 | 6 | 0.040 |
Why?
| | Dialysis | 1 | 2002 | 18 | 0.040 |
Why?
| | Verapamil | 1 | 2002 | 37 | 0.040 |
Why?
| | Fuchs' Endothelial Dystrophy | 1 | 2021 | 1 | 0.040 |
Why?
| | Isoenzymes | 1 | 2003 | 294 | 0.040 |
Why?
| | Lipid Peroxidation | 1 | 2002 | 168 | 0.040 |
Why?
| | Indocyanine Green | 1 | 2022 | 43 | 0.040 |
Why?
| | Amino Acids, Aromatic | 1 | 2001 | 6 | 0.040 |
Why?
| | Chemical Precipitation | 1 | 2002 | 39 | 0.040 |
Why?
| | Capsules | 1 | 2002 | 40 | 0.040 |
Why?
| | Phototherapy | 1 | 2022 | 49 | 0.040 |
Why?
| | Chronic Disease | 1 | 2008 | 1827 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2007 | 779 | 0.040 |
Why?
| | Tetrazolium Salts | 1 | 2001 | 18 | 0.040 |
Why?
| | Solutions | 1 | 2002 | 160 | 0.040 |
Why?
| | Antimetabolites | 1 | 2001 | 21 | 0.040 |
Why?
| | Vincristine | 1 | 2002 | 148 | 0.040 |
Why?
| | Indicators and Reagents | 1 | 2001 | 105 | 0.040 |
Why?
| | Spectrometry, Fluorescence | 1 | 2001 | 165 | 0.040 |
Why?
| | Drug Design | 1 | 2022 | 180 | 0.040 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2021 | 263 | 0.040 |
Why?
| | Thiazoles | 1 | 2001 | 139 | 0.040 |
Why?
| | Metal Nanoparticles | 1 | 2021 | 82 | 0.040 |
Why?
| | Ascorbic Acid | 1 | 2021 | 183 | 0.040 |
Why?
| | Hydrolysis | 1 | 2000 | 195 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 226 | 0.040 |
Why?
| | Liver X Receptors | 2 | 2011 | 29 | 0.040 |
Why?
| | Middle Aged | 5 | 2018 | 36619 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2001 | 882 | 0.040 |
Why?
| | Microtubules | 1 | 2021 | 226 | 0.040 |
Why?
| | Bronchi | 1 | 2001 | 263 | 0.040 |
Why?
| | Cold Temperature | 1 | 2001 | 208 | 0.040 |
Why?
| | Stereoisomerism | 1 | 1999 | 102 | 0.040 |
Why?
| | Mannheimia haemolytica | 1 | 1999 | 1 | 0.040 |
Why?
| | Receptor, TIE-2 | 1 | 2018 | 11 | 0.040 |
Why?
| | Instillation, Drug | 1 | 2018 | 9 | 0.030 |
Why?
| | Streptozocin | 1 | 2018 | 22 | 0.030 |
Why?
| | Fluorometry | 1 | 2018 | 19 | 0.030 |
Why?
| | Protein Conformation | 1 | 2001 | 916 | 0.030 |
Why?
| | Tears | 1 | 2018 | 29 | 0.030 |
Why?
| | Dithiothreitol | 1 | 1998 | 19 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2004 | 1130 | 0.030 |
Why?
| | Random Allocation | 1 | 1999 | 366 | 0.030 |
Why?
| | Monte Carlo Method | 1 | 2018 | 151 | 0.030 |
Why?
| | Olfactory Pathways | 1 | 1998 | 38 | 0.030 |
Why?
| | Protein Binding | 1 | 2004 | 2244 | 0.030 |
Why?
| | Cerebrospinal Fluid | 1 | 1998 | 88 | 0.030 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2018 | 141 | 0.030 |
Why?
| | G1 Phase | 1 | 2017 | 64 | 0.030 |
Why?
| | Static Electricity | 1 | 2017 | 113 | 0.030 |
Why?
| | Fatty Liver | 2 | 2011 | 252 | 0.030 |
Why?
| | Electroencephalography | 1 | 2020 | 576 | 0.030 |
Why?
| | Cell Cycle Checkpoints | 1 | 2017 | 97 | 0.030 |
Why?
| | Protease Inhibitors | 1 | 1997 | 103 | 0.030 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2017 | 180 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2017 | 335 | 0.030 |
Why?
| | Staining and Labeling | 1 | 2016 | 148 | 0.030 |
Why?
| | Terbutaline | 1 | 1996 | 7 | 0.030 |
Why?
| | 8-Bromo Cyclic Adenosine Monophosphate | 1 | 1996 | 18 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2016 | 173 | 0.030 |
Why?
| | Colforsin | 1 | 1996 | 47 | 0.030 |
Why?
| | Seizures | 1 | 2020 | 489 | 0.030 |
Why?
| | Monosaccharide Transport Proteins | 1 | 1996 | 55 | 0.030 |
Why?
| | Theophylline | 1 | 1996 | 41 | 0.030 |
Why?
| | Complement C3 | 1 | 2017 | 195 | 0.030 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 1996 | 73 | 0.030 |
Why?
| | Endocytosis | 1 | 2016 | 170 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2018 | 1298 | 0.030 |
Why?
| | Adrenergic beta-Agonists | 1 | 1996 | 91 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 504 | 0.030 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-6 | 1 | 2015 | 4 | 0.030 |
Why?
| | Visual Acuity | 1 | 2018 | 499 | 0.030 |
Why?
| | Epinephrine | 1 | 1996 | 160 | 0.030 |
Why?
| | Calcium Channel Blockers | 1 | 1996 | 165 | 0.030 |
Why?
| | Folic Acid | 1 | 2016 | 197 | 0.030 |
Why?
| | Proteolysis | 1 | 2015 | 174 | 0.030 |
Why?
| | Hepatitis B Surface Antigens | 1 | 2014 | 17 | 0.030 |
Why?
| | Hemoglobins | 1 | 2017 | 384 | 0.030 |
Why?
| | Zonula Occludens-1 Protein | 1 | 2014 | 17 | 0.030 |
Why?
| | Cycloheximide | 1 | 2014 | 42 | 0.030 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2014 | 16 | 0.030 |
Why?
| | ortho-Aminobenzoates | 1 | 1993 | 8 | 0.030 |
Why?
| | Barium Compounds | 1 | 1993 | 11 | 0.030 |
Why?
| | Chloride Channels | 1 | 1993 | 33 | 0.020 |
Why?
| | Diuretics | 1 | 1993 | 66 | 0.020 |
Why?
| | Tenon Capsule | 1 | 2013 | 3 | 0.020 |
Why?
| | Fundus Oculi | 1 | 2013 | 89 | 0.020 |
Why?
| | S-Phase Kinase-Associated Proteins | 1 | 2013 | 19 | 0.020 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2013 | 45 | 0.020 |
Why?
| | Arginine | 1 | 1995 | 264 | 0.020 |
Why?
| | Ion Channels | 1 | 1993 | 128 | 0.020 |
Why?
| | Haplorhini | 1 | 2013 | 51 | 0.020 |
Why?
| | Pepstatins | 1 | 2012 | 4 | 0.020 |
Why?
| | Lipofuscin | 1 | 2012 | 4 | 0.020 |
Why?
| | RNA Interference | 1 | 2015 | 472 | 0.020 |
Why?
| | Opsins | 1 | 2012 | 8 | 0.020 |
Why?
| | Cathepsin D | 1 | 2012 | 22 | 0.020 |
Why?
| | Autophagy | 1 | 2015 | 290 | 0.020 |
Why?
| | Antibody Formation | 1 | 2014 | 290 | 0.020 |
Why?
| | Oxidants | 1 | 2013 | 100 | 0.020 |
Why?
| | beta Catenin | 1 | 2015 | 250 | 0.020 |
Why?
| | Boron Compounds | 1 | 2012 | 28 | 0.020 |
Why?
| | Glaucoma Drainage Implants | 1 | 2013 | 47 | 0.020 |
Why?
| | Immunoblotting | 1 | 2012 | 294 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2013 | 186 | 0.020 |
Why?
| | Caspase 3 | 1 | 2013 | 240 | 0.020 |
Why?
| | Irritants | 1 | 2012 | 42 | 0.020 |
Why?
| | Mechlorethamine | 1 | 2012 | 52 | 0.020 |
Why?
| | Catalytic Domain | 1 | 2012 | 235 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 1996 | 2092 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2014 | 834 | 0.020 |
Why?
| | Brimonidine Tartrate | 1 | 2011 | 10 | 0.020 |
Why?
| | Rats, Transgenic | 1 | 2011 | 20 | 0.020 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2013 | 198 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 1996 | 2838 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2013 | 337 | 0.020 |
Why?
| | Mustard Gas | 1 | 2012 | 77 | 0.020 |
Why?
| | Homeostasis | 1 | 2015 | 646 | 0.020 |
Why?
| | Desmosterol | 1 | 2011 | 1 | 0.020 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2011 | 132 | 0.020 |
Why?
| | COS Cells | 1 | 2011 | 173 | 0.020 |
Why?
| | Androstenes | 1 | 2011 | 16 | 0.020 |
Why?
| | Chemokine CCL2 | 1 | 2011 | 112 | 0.020 |
Why?
| | Hep G2 Cells | 1 | 2011 | 74 | 0.020 |
Why?
| | Oxidoreductases Acting on CH-CH Group Donors | 1 | 2011 | 27 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2012 | 404 | 0.020 |
Why?
| | Laser Coagulation | 1 | 2011 | 80 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2011 | 371 | 0.020 |
Why?
| | Phosphorylation | 1 | 2015 | 1724 | 0.020 |
Why?
| | Intestinal Absorption | 1 | 1991 | 103 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2013 | 615 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2016 | 1432 | 0.020 |
Why?
| | Adult | 4 | 2018 | 41087 | 0.020 |
Why?
| | Antibodies, Viral | 1 | 2014 | 689 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2014 | 901 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1361 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 1036 | 0.020 |
Why?
| | RNA, Ribosomal, 18S | 1 | 2009 | 21 | 0.020 |
Why?
| | Membrane Potentials | 1 | 2010 | 278 | 0.020 |
Why?
| | Ketorolac | 1 | 2009 | 33 | 0.020 |
Why?
| | Gene Amplification | 1 | 2009 | 116 | 0.020 |
Why?
| | ATP Binding Cassette Transporter 1 | 1 | 2008 | 13 | 0.020 |
Why?
| | Foam Cells | 1 | 2008 | 17 | 0.020 |
Why?
| | Young Adult | 2 | 2018 | 14330 | 0.020 |
Why?
| | Sterol Regulatory Element Binding Protein 1 | 1 | 2008 | 56 | 0.020 |
Why?
| | Hypertriglyceridemia | 1 | 2008 | 45 | 0.020 |
Why?
| | DNA Primers | 1 | 2009 | 487 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1031 | 0.020 |
Why?
| | Apolipoproteins E | 1 | 2008 | 97 | 0.020 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2008 | 117 | 0.020 |
Why?
| | Intestines | 1 | 2011 | 351 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2015 | 3125 | 0.020 |
Why?
| | Feces | 1 | 2011 | 496 | 0.020 |
Why?
| | Sodium Hydroxide | 1 | 2007 | 5 | 0.020 |
Why?
| | Fibroblasts | 1 | 2013 | 1034 | 0.020 |
Why?
| | Cell Fractionation | 1 | 2007 | 50 | 0.020 |
Why?
| | Receptors, Peptide | 1 | 2007 | 18 | 0.020 |
Why?
| | Nerve Tissue Proteins | 1 | 2011 | 597 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2010 | 561 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2011 | 650 | 0.010 |
Why?
| | Cytomegalovirus | 1 | 2007 | 172 | 0.010 |
Why?
| | Lipopolysaccharides | 1 | 2009 | 861 | 0.010 |
Why?
| | Biomedical Research | 1 | 2010 | 729 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2921 | 0.010 |
Why?
| | Phlorhizin | 1 | 1996 | 2 | 0.010 |
Why?
| | Phloretin | 1 | 1996 | 2 | 0.010 |
Why?
| | Levobunolol | 1 | 1993 | 1 | 0.010 |
Why?
| | Betaxolol | 1 | 1993 | 1 | 0.010 |
Why?
| | Atenolol | 1 | 1993 | 8 | 0.010 |
Why?
| | Nasolacrimal Duct | 1 | 1993 | 12 | 0.010 |
Why?
| | Kinetics | 1 | 1996 | 1553 | 0.010 |
Why?
| | Glucose | 1 | 1996 | 1053 | 0.000 |
Why?
| | Aged | 1 | 2009 | 26432 | 0.000 |
Why?
|
|
Kompella's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|